SZLSF (StageZero Life Sciences) Change In Working Capital: $1.13 Mil (TTM As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZLSF StageZero Life Sciences Ltd SZLSF
10 GF Score
Price $0.00
View Full Analysis

What is StageZero Life Sciences Change In Working Capital?

StageZero Life Sciences SZLSF 10 Change In Working Capital is $1.13 Mil as of Sep. 2024. GuruFocus rates SZLSF with a GF Score™ of 10/100.

StageZero Life Sciences's change in working capital for the quarter that ended in Sep. 2024 was $0.32 Mil.

StageZero Life Sciences's change in working capital for the fiscal year that ended in Dec. 2022 was $3.71 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

StageZero Life Sciences Change In Working Capital Related Terms

StageZero Life Sciences Change In Working Capital Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Change In Working Capital Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Change In Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 -0.38 -0.08 -0.46 3.71

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.68 0.21 0.61 0.32
SZLSF
10GF Score
StageZero Life Sciences Ltd SZLSF
Change In Working Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.13 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Working Capital of $1.13 Mil mean?
StageZero Life Sciences (SZLSF) has a Change In Working Capital of $1.13 Mil as of Sep. 2024. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for StageZero Life Sciences.
Is StageZero Life Sciences' Change In Working Capital too high?
StageZero Life Sciences' current Change In Working Capital is $1.13 Mil. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Change In Working Capital compare to IDTA and TTOO?
StageZero Life Sciences' Change In Working Capital of $1.13 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Working Capital for a Medical Diagnostics & Research company?
A good Change In Working Capital depends on the Medical Diagnostics & Research industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Working Capital mean?
A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for StageZero Life Sciences. StageZero Life Sciences's current Change In Working Capital is $1.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (SZLSF) has a current Change In Working Capital of $1.13 Mil. The current Change In Working Capital is $1.13 Mil. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Working Capital calculated?
Change In Working Capital is calculated from a company's financial statements. For StageZero Life Sciences (SZLSF), the current Change In Working Capital is $1.13 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for SZLSF

Change In Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price